Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

Completed · Phase 1/Phase 2

Conditions studied: Alopecia

In brief

The primary objective of this proposal is to conduct a study that assesses the safety, feasibility and efficacy of using PRP to treat this type of hair loss.

Key facts

Study ID

NCT03488108

Run by

Mayo Clinic

People needed

20

Starts

2017-01-23

Expected to finish

2019-06-17

Last updated by the study team

2020-04-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Only female patients are eligible
• Patients must be 18 years of age or older
• Patients must have Androgenic Alopecia Grade I-II by Ludwig Classification
• Patients must have been on stable birth control if premenopausal.
• Patients are able and willing to provide written informed consent after the nature of the study is fully explained

You may not qualify if…

• Patients with clinically abnormal hematology, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator
• Patients who have undergone topical and systemic therapies for hair loss 3 months prior to the procedure
• Patients who have used any cosmetic product meant to address hair loss 3 months prior to enrollment
• Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry.
• Patients previously having undergone hair transplant surgery prior to study entry
• Patients who are pregnant or currently breast-feeding children as Rogaine for Women is contra indicated for these women
• Patients who have taken spironolactone in the 3 months prior to study participation
• Patients with systemic, rheumatic or inflammatory disease or who are immunosuppressed
• Patients with ongoing infectious disease, including HIV and hepatitis
• Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes
• Patients participating in a study of an experimental drug or medical device within 30 days of study entry
• Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer in the last 5 years.
• Patients taking antiaggregating therapy
• Patients on anticoagulant therapy
• Patients with tendency to keloid formation
• Patients with uncompensated diabetes
• Patients with active skin disease or skin infection at intended treatment areas

Where it is running

• Mayo Clinic Florida — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.